On February 16, Wuxi Apptec Co.Ltd(603259) released the annual performance express of 2021. During the reporting period, the company achieved an operating revenue of about 22.902 billion yuan, a year-on-year increase of 38.5%; The net profit attributable to shareholders of listed companies was about 5.097 billion yuan, a year-on-year increase of 72.19%. The reason for the strong growth of performance is mainly affected by the main business and non recurring profit and loss items.
In terms of main business, the integrated chemical business segment continued to build an “integrated, end-to-end” crdmo (contract research, development and production organization) business, with strong order demand, which promoted the rapid growth of annual sales revenue in 2021; It is estimated that the revenue growth rate of the chemical business sector in 2022 will nearly double that in 2021.
In 2021, the laboratory analysis and testing business, clinical cro / SMO business and biology business under the testing business also achieved strong growth; It is expected that the revenue growth of these businesses in 2022 will continue the momentum of recent years. During the reporting period, Wuxi Apptec Co.Ltd(603259) continuously improved the capacity utilization and further revealed the scale effect by continuously optimizing the operation efficiency.
During the reporting period, the net income impact of the company’s non recurring profit and loss items increased compared with the same period of the previous year, mainly because the fair value of the company’s H-share convertible bond derivative financial instruments is affected by the change of the company’s H-share price, and the loss of non cash book fair value in 2021 is expected to decrease by about RMB 349 million compared with the loss of the previous year; In addition, during the reporting period, the company completed the transaction of selling small molecule toxin molecules and connecting sub businesses and related assets to Changzhou Yaoming Helian Biotechnology Co., Ltd., a wholly-owned subsidiary of Wuxi Yaoming Helian Biotechnology Co., Ltd., and obtained a net income of about 274 million yuan from the disposal of assets.
